Tear Sheet

Company Overview

HTG Molecular Diagnostics, Inc.'s mission is to empower precision medicine at the local level. The company’s proprietary HTG EdgeSeq technology automates multiplexed molecular profiling of nucleic acids in a wide variety of solid and liquid samples, even when very limited in amount. The extraction free workflow paired with detection by next-generation sequencing offers many advantages and enables meaningful applications, such as identifying biomarkers important for precision medicine, understanding the clinical relevance of these biomarkers, and, ultimately, identifying treatment options.

Events

Date Event Details
Summary Toggle Aug 6, 2019 at 4:30 PM EDT
Tuesday, August 6, 2019
Time: 4:30pm Eastern Time
Toll Free: (877) 407-0789
International: (201) 689-8562
Conference ID: 13692789
Webcast: http://public.viavid.com/index.php?id=135458

Stock Quote

Copyright West LLC. Minimum 15 minutes delayed.

News Releases

Date Title and Summary
Toggle Summary HTG Molecular Diagnostics Announces Pricing of $20.0 Million Aggregate Financing, Consisting of $16.6 Million Public Offering of Common Stock and $3.5 Million Concurrent Private Placement
TUCSON, Ariz. --(BUSINESS WIRE)--Sep. 20, 2019-- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced the pricing of an underwritten public offering of 25,476,989 shares of its common stock at a price to the
Toggle Summary HTG Molecular Diagnostics Announces Proposed Public Offering of Common Stock
TUCSON, Ariz. , Sept. 19, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that it intends to offer and sell, subject to market and other conditions, shares of its common stock in an
Toggle Summary HTG Molecular Diagnostics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
TUCSON, Ariz. , Aug. 20, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that, on August 15, 2019 the Compensation Committee of its Board of Directors granted inducement stock options
Toggle Summary HTG Molecular Diagnostics Reports Second Quarter 2019 Results
Product and product-related services revenue increased by 119% and 89%, respectively,  compared to the three and six-month periods in the prior year Call scheduled for today, August 6 , at 4:30pm ET TUCSON, Ariz. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc.
Toggle Summary HTG Molecular to Present Corporate Overview at the Canaccord Genuity 39th Annual Growth Conference
TUCSON, Ariz. , July 25, 2019 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics , Inc. (Nasdaq: HTGM) (HTG), a diagnostic company whose mission is to advance precision medicine, today announced that John Lubniewski , President and CEO, will present a corporate overview at the Canaccord Genuity 39 th

Stock Chart

SEC Filings

Filing date Description

Form of prospectus disclosing information, facts, events covered in both forms 424B2, 424B3

Report of unscheduled material events or corporate event

Statement of changes in beneficial ownership of securities

Statement of changes in beneficial ownership of securities

Report of unscheduled material events or corporate event